Co-Diagnostics, Inc. to Present at Utah Mosquito Abatement Association Conference
the website of the
Vector is the term used to describe an organism that transmits infectious disease across human or animal populations. Co-Diagnostics’ vector control program will involve technology provided by the Company for use in vector control services to test mosquito populations where the insect is known or suspected to act as a vector. The UMAA conference will include a brief presentation of the technology used by the Company in vector control programs, as well as meetings with several department heads and directors of organizations across the state involved with control and abatement of mosquitos carrying diseases like West Nile virus.
“The opportunity to provide vector control tests extends throughout vast
regions of the world that are home to more than 2 billion people who are
vulnerable to serious infections from mosquitoes.
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions.Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in liquid biopsy and SNP detection, (iv) use of the Company’s liquid biopsy tests by laboratories, (v) capital resources and runway needed to advance the Company’s products and markets, (vi) increased sales in the near-term, (vii) flexibility in managing the Company’s balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances.Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Co-Diagnostics Investor Relations
Lytham Partners, LLC
Joe Diaz, Robert Blum and Joe Dorame